The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis

Campanati, Anna; Ganzetti, Giulia; Sario, A. Di; Damiani, Adriani Paganini; Sandroni, Lucia; Rosa, Laura; Benedetti, Antonio; Offidani, Annamaria

doi:10.1007/s00535-012-0678-9

Cited by 67 publications

(65 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Dominguez and coworkers revealed only benefit on b-cell function with etanercept treatment, suggesting that it may not be a valuable treatment for NAFLD. However, others found that etanercept reduced the risk of developing hepatic fibrosis in patients with MetS (Campanati et al, 2013). In this study, patients with psoriasis, which are at risk of developing NAFLD and MetS probably because of underlying insulin resistance, were treated with etanercept and compared to patients treated with UVA.…”

Section: Treatment Of Mets and Nafldmentioning

confidence: 94%

“…The group receiving etanercept showed significant reductions in transaminases, CRP and fasting insulin levels, and improved HOMA index, indicating that etanercept may be efficacious in reducing the development of NAFLD and MetS in patients with psoriasis. However, there were some limitations in this study, such as the diagnosis of NAFLD, which was done by ultrasonography (Campanati et al, 2013).…”

Section: Treatment Of Mets and Nafldmentioning

confidence: 98%

See 1 more Smart Citation

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Asrih

Jornayvaz

2015

Molecular and Cellular Endocrinology

260

185

View full text Add to dashboard Cite

Section: Treatment Of Mets and Nafldmentioning

confidence: 94%

Section: Treatment Of Mets and Nafldmentioning

confidence: 98%

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Asrih

Jornayvaz

2015

Molecular and Cellular Endocrinology

260

185

View full text Add to dashboard Cite

“…Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis and activated CD4 + and CD8 + T-cell infiltrates in the dermis and epidermis are the most common detectable histologic features in psoriasis [25] . The pathogenesis of psoriasis is characterized by the involvement of both innate and adaptive immunity.…”

Section: Psoriasis: a Systemic Diseasementioning

confidence: 99%

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases. Core tip: The review focuses on the multiple physiopathogenetic aspects of the possible link between psoriasis and non-alcoholic fatty liver disease (NAFLD) emphasizing the most recent scientific data. The importance of the multidisciplinary approach to patients affected by psoriasis is underlined and the therapeutic options to treat concomitant psoriasis and NAFLD is discussed evaluating the risk benefit of both biologic and non-biologic therapies.Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 Available from:

show abstract

“…Ustekinumab is not associated with weight gain in patients with chronic plaque psoriasis [49]. The effects of TNF-α inhibitors therapy on insulin sensitivity are controversial [50,51]. The effects of anti-TNFs on glycaemic parameters and insulin resistance in patients with psoriasis have been addressed mostly in small studies by means of the HOMA and the Quantitative Insulin Sensitivity Check Index (QUICKI], two widely used non-invasive surrogate markers of insulin resistance and sensitivity, respectively.…”

Section: Management Of Patients With Moderate To Severe Psoriasis Andmentioning

confidence: 99%

Systemic therapy of psoriasis in diabetic patients

Gisondi¹,

Perazzolli²,

Giglio³

et al. 2015

Glob Dermatol

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of worldwide population. Moderate to severe psoriasis is frequently associated with metabolic disorders including diabetes, obesity, dyslipidaemia, metabolic syndrome and non-alcoholic fatty liver disease. In particular, the prevalence of diabetes in patients with psoriasis ranges from 5 to 54%. Most of the studies found that the prevalence of diabetes is higher in patients with moderate to severe psoriasis compared to mild disease. The association between psoriasis and diabetes could be explained considering several factors including a common genetic background, the high prevalence of metabolic risk factors for diabetes in patients with psoriasis as well as unhealthy life-styles such heavy drinking, over-eating and sedentary, which are common in patients with psoriasis. From a clinical prospective, the understanding of the patients in the context of metabolic comorbidities including diabetes is very important to ensure that treatment is tailored to meet the individual patient needs. Indeed, some pharmacological treatments may negatively affect metabolic comorbidities, and have important interactions with drugs that are commonly used to treat them. Non-pharmacological intervention such as diet and physical exercise could both improve the response to treatments for psoriasis and reduce the risk of diabetes and cardiovascular events.

show abstract

The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis

Cited by 67 publications

References 28 publications

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Systemic therapy of psoriasis in diabetic patients

Contact Info

Product

Resources

About